Proteomics International Signs Long-Term Partnership with Dutch/Australian Company BiosanaPharma

Proteomics International Laboratories Ltd (ASX:PIQ), has recently announced a long-term partnership with Dutch/Australian company BiosanaPharma to test a new treatment for allergic asthma.

KEY TAKEAWAYS: 

• The partnership marks the start of a new service in release testing and long-term and accelerated stability testing for biosimilars, backed by ISO 17035 accreditation.
• Agreement is Proteomics International’s largest biosimilars contract to date with a value in excess of $200,000.
• The global biosimilars drug market surpassed US$ 3.3billion in 2016 and is expected to triple in size to reach US$10.5 billion by 2022 as pharmaceutical companies seek to replicate a host of blockbuster drugs coming off patent.

Dr Lipscombe said stability and accelerated testing for biosimilars was a new area of importance for Proteomics International, with the long-term service attracting long-term clients. “Only specialist laboratories are able to take on this work because if a fridge or freezer fails, due to a power cut for instance, you could lose six months of testing data,” he said. Our extensive ISO 17025 laboratory certifications set us apart as the most accredited protein testing laboratory in the world.

BiosanaPharma’s Chief Operating and Chief Scientific Officer Jaap Wieling remarked that the quality and reliability of service was key to choosing Proteomics International as a partner for their exciting new drug. “Australia’s advanced R&D environment supports our desire to make antibody biosimilars efficiently and affordably,” he said.

Request Information